HimsworthHP. Diabetes mellitus: Its differentiation into insulin sensitive and insulin insensitive types. Lancet1936; i: 127–30.
2.
HimsworthHPKerrRB. Insulin-sensitive and insulin-insensitive types of diabetes mellitus. Clin Sci1939; 4: 119–52.
3.
National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes1979; 28: 1039–57.
4.
World Health Organization Expert Committee on Diabetes Mellitus. Second Report. Technical Report Series 646. Geneva: World Health Organization, 1980.
5.
YalowRSBersonSA. Immunoassay of endogenous plasma insulin in man. J Clin Invest1960; 39: 1157–75.
6.
YalowRSBersonSA. Plasma insulin concentration in nondiabetic and early diabetic subjects—determination by a new sensitive immunoassay technique. Diabetes1960; 9: 254–60.
ShenS-WReavenGMFarquharJW. Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest1970; 49: 2151–60.
9.
ReavenGM. Insulin resistance in noninsulin-dependent diabetes mellitus—does it exist and can it be measured?Am J Med1983; 74 (suppl 1A): 3–17.
10.
ReavenGM. Role of insulin resistance in human disease. Diabetes1988; 37: 1595–607.
11.
KahnCR. Insulin resistance, insulin insensitivity, and insulin unresponsiveness: A necessary distinction. Metabolism1978; 27: 1893–902.
12.
HollenbeckCReavenGM. Variation in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab1987; 64: 1169–73.
13.
Yki-JärvinenH.Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia1995; 38: 1378–88.
14.
MollerDEFlierJS. Insulin resistance—mechanisms, syndromes and implications. N Engl J Med1991; 325: 938–48.
15.
SobeyWJBeerSFCarringtonCAClarkPMSFrankBHGrayIPSensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65–66 split and 32–33 split proinsulins. Biochem J1989; 260: 535–41.
16.
RhodesCJAlarcónC.What β-cell defect could lead to hyperproinsulinaemia in NIDDM? Some clues from recent advances made in understanding the proinsulin-processing mechanism. Diabetes1994; 43: 511–7.
17.
GerichJE. Is muscle the major site of insulin resistance in type 2 (noninsulin-dependent) diabetes mellitus?Diabetologia1991; 34: 607–10.
18.
DeFronzoRABonadonnaRCFerranniniE.Pathogenesis of NIDDM. A balanced overview. Diabetes Care1992; 15: 318–68.
19.
DeFronzoRAFerranniniESimonsonDC. Fasting hyperglycaemia in noninsulin-dependent diabetes mellitus: Contribution of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism1989; 38: 387–95.
20.
Beck-NielsenHHother-NielsenOVaagAAlfordF.Pathogenesis of type 2 (noninsulin-dependent) diabetes mellitus: The role of skeletal muscle glucose uptake and hepatic glucose production in the development of hyperglycaemia. A critical comment. Diabetologia1994; 37: 217–21.
21.
ReavenGM. The fourth musketeer—from Alexandre Dumas to Claude Bernard. Diabetologia1995; 38: 3–13.
22.
OlefskyJFarquharJWReavenGM. Relationship between fasting plasma insulin level and resistance to insulin-mediated glucose uptake in normal and diabetic subjects. Diabetes1973; 22: 507–13.
23.
MatthewsDRHoskerJPRudenskiASNaylorBATreacherDFTurnerRC. Homeostasis model assessment: Insulin resistance and β-cell function from plasma glucose and insulin concentrations in man. Diabetologia1985; 28: 412–9.
24.
PhillipsDIWClarkPMHalesCNOsmondC.Understanding oral glucose tolerance: Comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med1994; 11: 286–92.
25.
WarehamNJPhillipsDIWByrneCDHalesCN. The 30 minute insulin incremental response in an oral glucose tolerance test as a measure of insulin secretion. Diabet Med1995; 12: 931.
26.
GalvinPWardGWaltersJPestellRKoschmannMVaagAA simple method for quantitation of insulin sensitivity and insulin release from an intravenous glucose tolerance test. Diabet Med1992; 9: 921–8.
27.
BergmanRNIderY ZiyaBowdenCRCobelliC.Quantitative estimation of insulin sensitivity. Am J Physiol1979; 236: E667–77.
28.
BergmanRNPhillipsLSCobelliC.Physiologic evaluation of factors controlling glucose tolerance in man: Measurement of insulin sensitivity and β cell glucose sensitivity from the response to intravenous glucose. J Clin Invest1981; 68: 1456–67.
29.
HoskerJPMatthewsDRRudenskiASBurnettMADarlingPBownEGContinuous infusion of glucose with model assessment: Measurement of insulin resistance and β-cell function in man. Diabetologia1985; 28: 401–1.
30.
DeFronzoRATobinJDAndresR.Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol1979; 237: E214–23.
31.
MitrakouAVuorinen-MarkkolaHRaptisGToftIMokanMStrumphPSimultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycaemic clamp. J Clin Endocrinol Metab1992; 75: 379–82.
32.
HaranoYOhgakuSHidakaHHanedaKKikkawaRShigetaYGlucose, insulin and somatostatin infusion for the determination of insulin sensitivity. J Clin Endocrinol Metab1977; 45: 1124–7.
33.
NagulesparanMSavagePJUngerRHBennettPH. A simplified method using somatostatin to assess in vivo insulin resistance over a range of obesity. Diabetes1979; 28: 980–3.
34.
ProiettoJHarewoodMAitkenPNankervisACarusoGAlfordF.Validation of a practical in vivo insulin dose-response curve in man. Metabolism1982; 31: 354–61.
35.
GroopLCBonnadonnaRCDelPratoSRatheiserKZyckKFerranniniEGlucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus—evidence for multiple sites of insulin resistance. J Clin Invest1989; 84: 205–13.
36.
SchadeDSEatonRP. Dose-response to insulin in man: Differential effects on glucose and ketone body regulation. J Clin Endocrinol Metab1977; 44: 1038–53.
37.
SaccàLSherwinRHendlerRFeligP.Influence of continuous physiologic hyperinsulinaemia on glucose kinetics and counterregulatory hormones in normal and diabetic humans. J Clin Invest1979; 63: 849–57.
38.
HalePJBlackENattrassM.Metabolic effects of low-dose incremental insulin infusion in diabetic man. Horm Metab Res1986; 18: 129–33.
39.
AkinmokunASelbyPLRamaiyaKAlbertiKGMM. The short insulin tolerance test for determination of insulin sensitivity: A comparison with the euglycaemic clamp. Diabet Med1992; 9: 432–7.
40.
BonoraEMoghettiPZancanaroCCigoliniMQuerenaMCacciatoriVEstimates of in vivo insulin action in man: Comparison of insulin tolerance tests with euglycaemic and hyperglycaemic glucose clamp studies. J Clin Endocrinol Metab1989; 68: 374–8.
41.
PolonskyKSGivenBDVan CauterE.Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest1988; 81: 442–8.
42.
LangDAMatthewsDRPetoJTurnerRC. Cyclic oscillation of basal plasma glucose and insulin concentrations in human beings. N Engl J Med1979; 301: 1023–7.
43.
HollenbeckCBChenY-DIReavenGM. Relationship between the plasma insulin response to oral glucose and insulin-stimulated glucose utilisation in normal subjects. Diabetes1984; 33: 460–3.
44.
SteilGMMurrayJBergmanRNBuchananTA. Repeatability of insulin sensitivity and glucose effectiveness from the minimal model. Implications for study design. Diabetes1994; 43: 1365–71.
45.
GroopLCWidénEFerranniniE.Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: Errors of metabolism or of methods?Diabetologia1993; 36: 1326–31.
46.
CzechM.The nature and regulation of the insulin receptor: Structure and function. Ann Rev Physiol1985; 47: 357–81.
47.
KoltermanOGGrayRSGriffinJBursteinPInselJScarlettJAReceptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes. J Clin Invest1981; 68: 957–69.
48.
ShiaMAPilchPF. The beta-subunit of the insulin receptor is an insulin-activated protein kinase. Biochemistry1983; 22: 717–21.
49.
KahnCRWhiteMF. The insulin receptor and the molecular mechanism of insulin action. J Clin Invest1988; 82: 1151–6.
50.
SunXJRothenbergPKahnCRBackerJMArakiEWildenPAStructure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature1991; 352: 73–7.
51.
ArakiELipesMAPattiMEBruningJCHaagB3rdJohnsonRSAlternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature1994; 372: 186–90.
52.
KochCAAndersonDMoranMFEllisCPawsonT.SH2 and SH3 domains: Elements that control interactions of cytoplasmic signalling proteins. Science1991; 252: 668–74.
53.
TantiJFGrémeauxTVan ObberghenELe Marchand-BrustelY.Insulin receptor substrate 1 is phosphorylated by the serine kinase activity of phosphatidylinositol 3-kinase. Biochem J1994; 304: 17–21.
54.
LavanBELienhardGE. Insulin signalling and the stimulation of glucose transport. Biochem Soc Trans1994; 22: 676–80.
55.
DentonRMTavareJM. Does mitogen-activated-protein kinase have a role in insulin action? The cases for and against. Eur J Biochem1995; 227: 597–611.
56.
LeeC-HLiWNishimuraRZhouMBatzerAGMyersMGJrNck associates with the SH2 domain docking protein IRS-1 in insulin-stimulated cells. Proc Natl Acad Sci USA1993; 90: 11713–7.
57.
CheathamBKahnCR. Insulin action and the insulin signalling network. Endocr Rev1995; 16: 117–42.
58.
WhiteMF. The insulin signalling system and the IRS proteins. Diabetologia1997; 40 (Suppl 2): S2–17.
59.
YamauchiTTobeKTamemotoHUekiKKaburagiYYamamoto-HondaRInsulin signalling and insulin actions in the muscles and livers of insulin-resistant, insulin receptor substrate 1-deficient mice. Mol Cell Biol1996; 16: 3074–84.
60.
ThorensB.Glucose transporters in the regulation of intestinal, renal, and liver glucose fluxes. Am J Physiol1996; 270: G541–53.
YangJClarkeJFEsterCJYoungPWKasugaMHolmanGD. Phosphatidylinositol 3-kinase acts at an intracellular membrane site to enhance GLUT4 exocytosis in 3T3-L1 cells. Biochem J1996; 313: 125–31.
63.
MarshallSGarveyWTTraxingerRR. New insights into the metabolic regulation of insulin action and insulin resistance: Role of glucose and amino acids. FASEB J1991; 5: 3031–6.
KrookAO'RahillyS.Mutant insulin receptors in syndromes of insulin resistance. Baillière's Clin Endocrinol Metab1996; 10: 97–122.
66.
KingGLKahnCRRechlerMMNissleySP. Direct demonstration of separate receptors for growth and metabolic activities of insulin and multiplication-stimulating activity (an insulin-like growth factor) using antibodies to the insulin receptor. J Clin Invest1980; 66: 130–40.
67.
TaylorSI. Receptor defects in patients with extreme insulin resistance. Diabetes Metab Rev1985; 1: 171–202.
68.
GeffnerMEGoldeDW. Selective insulin action on skin, ovary and heart in insulin resistant states. Diabetes Care1988; 11: 500–5.
69.
BoynsDRCrossleyJNAbramsMEJarrettRJKeenH.Oral glucose tolerance and related factors in a normal population sample. I. Blood sugar, plasma insulin, glyceride and cholesterol measurements and the effects of age and sex. BMJ1969; i: 595–8.
70.
WelbornTAStenhouseNSJohnstoneCG. Factors determining serum insulin response in a population sample. Diabetologia1969; 5: 263–6.
71.
HalePJWrightJVNattrassM.Differences in insulin sensitivity between normal men and women. Metabolism1985; 34: 1133–8.
72.
Yki-JärvinenH.Sex and insulin sensitivity. Metabolism1984; 33: 1011–5.
73.
AmielSASherwinRSSimonsonDCLauritanoAATamborlaneWV. Impaired insulin action in puberty—a contributory factor to poor glycaemic control in adolescents with diabetes. N Engl J Med1986; 315: 215–9.
74.
RoweJWMinakerKLPallottaJAFlierJS. Characterization of the insulin resistance of aging. J Clin Invest1983; 71: 1581–7.
75.
FinkRIKoltermanOGGriffinJOlefskyJM. Mechanisms of insulin resistance of aging. J Clin Invest1983; 71: 1523–35.
76.
CoonPJRogusEMDrinkwaterDMullerDCGoldbergAP. Role of body fat distribution in the decline in insulin sensitivity and glucose tolerance with age. J Clin Endocrinol Metab1992; 75: 1125–32.
77.
KohrtWMKirwanJPStatenMABoureyREKingDSHolloszyJO. Insulin resistance in aging is related to abdominal obesity. Diabetes1993; 42: 273–81.
78.
BodenGChenXDeSantisRAKendrickZ.Effects of age and body fat on insulin resistance in healthy men. Diabetes Care1993; 16: 728–733.
79.
LohmannDLieboldFHeilmannWSengerHPohlA.Diminished insulin response in highly trained athletes. Metabolism1978; 27: 521–4.
80.
KingDSDalskyGPClutterWEYoungDAStatenMACryerPEEffects of lack of exercise on insulin secretion and action in trained subjects. Am J Physiol1988; 254: E537–42.
81.
DevlinJTHortonES. Effects of prior high-intensity exercise on glucose metabolism in normal and insulin-resistant men. Diabetes1985; 34: 973–9.
82.
DevlinJTHirshmanMHortonEDHortonES. Enhanced peripheral and splanchnic insulin sensitivity in NIDDM men after single bout of exercise. Diabetes1987; 36: 434–9.
83.
BogardusC.Insulin resistance in the pathogenesis of NIDDM in Pima Indians. Diabetes Care1993; 16 (Suppl 1): 228–31.
84.
BanerjiMALebovitzHE. Insulin-sensitive and insulin-resistant variants in NIDDM. Diabetes1989; 38: 784–92.
85.
DowlingHJPi-SunyerFX. Race-dependent health risks of upper body obesity. Diabetes1993; 42: 537–43.
86.
DowlingHJFriedSKPi-SunyerFX. Insulin resistance in adipocytes of obese women: Effect of body fat distribution and race. Metabolism1995; 44: 987–95.
87.
McKeiguePMMarmotMGCourtYD SyndercombeCottierDERahmanSRiemersmaRA. Diabetes, hyperinsulinaemia, and coronary risk factors in Bangladeshis in East London. Br Heart J1988; 60: 390–6.
88.
McKeiguePMShahBMarmotMG. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet1991; 337: 382–6.
89.
HaffnerSMSternMPHazudaHPMitchellBDPattersonJK. Increased insulin concentration in nondiabetic offspring of diabetic parents. N Engl J Med1988; 319: 1297–301.
90.
GeldingSVColdhamNNiththyananthanRAnyaokuVJohnstonDG. Insulin resistance with respect to lipolysis in non-diabetic relatives of European patients with type 2 diabetes. Diabet Med1995; 12: 66–73.
91.
MigdalisINZachariadisDKalogeropoulouKNounopoulosCBouloukosASamartzisM.Metabolic abnormalities in offspring of NIDDM patients with a family history of diabetes mellitus. Diabet Med1996; 13: 434–40.
92.
VaagAAlfordFBeck-NielsenH.Intracellular glucose and fat metabolism in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM): Acquired versus genetic metabolic defects?Diabet Med1996; 13: 806–15.
93.
OseiKCottrellDAOrabellaMM. Insulin sensitivity, glucose effectiveness and body fat distribution pattern in nondiabetic offspring of parents with NIDDM. Diabetes Care1991; 14: 890–6.
94.
KeysAFidanzaFKarvonenMJKimuraNTaylorHL. Indices of relative weight and obesity. J Chron Dis1972; 25: 329–43.
95.
KoltermanOGInselJSaekowMOlefskyJM. Mechanism of insulin resistance in human obesity. Evidence for receptor and postreceptor defects. J Clin Invest1980; 65: 1272–84.
96.
PragerRWallacePOlefskyJM. In vivo kinetics of insulin action on peripheral glucose disposal and hepatic glucose output in normal and obese subjects. J Clin Invest1986; 78: 472–81.
97.
LaaksoMEdelmanSVBrechtelGBaronAD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest1990; 85: 1844–52.
98.
BakirSMJarrettRJ. The effects of a low-dose intravenous insulin infusion upon plasma glucose and non-esterified fatty acid levels in very obese and non-obese human subjects. Diabetologia1981; 20: 592–96.
99.
MeylanMHennyCTemlerEJequierEFelberJP. Metabolic factors in the insulin resistance in human obesity. Metabolism1987; 36: 256–61.
100.
HalePJSinghBMCraseJBaddeleyRMNattrassM.Following weight loss in massively obese patients correction of the insulin resistance of fat metabolism is delayed relative to the improvement in carbohydrate metabolism. Metabolism1988; 37: 411–7.
101.
RobertsonDASinghBMNattrassM.Effect of obesity on circulating intermediary metabolite concentrations in the absence of impaired glucose tolerance. Int J Obes1991; 15: 635–45.
102.
RobertsonDASinghBMHalePJNattrassM.Effects of morbid obesity on insulin clearance and insulin sensitivity in several aspects of metabolism as measured by low-dose insulin infusion. Metabolism1992; 41: 604–12.
103.
HollenbeckCBChenY-DIReavenGM. A comparison of the relative effects of obesity and noninsulin-dependent diabetes mellitus on in vivo insulin-stimulated glucose utilisation. Diabetes1984; 33: 622–6.
104.
FirthRBellPRizzaR.Insulin action in noninsulin-dependent diabetes mellitus: The relationship between hepatic and extrahepatic insulin resistance and obesity. Metabolism1987; 36: 1091–5.
105.
LudvikBNolanJJBalogaJSacksDOlefskyJ.Effect of obesity on insulin resistance in normal subjects and patients with NIDDM. Diabetes1995; 44: 1121–5.
106.
BogardusCLilliojaSMottDMHollenbeckCReavenGM. Relationship between degree of obesity and in vivo insulin action in man. Am J Physiol1985; 248: E286–91.
107.
CampbellPJGerichJE. Impact of obesity on insulin action in volunteers with normal glucose tolerance: Demonstration of a threshold for the adverse effect of obesity. J Clin Endocrinol Metab1990; 70: 1114–8.
108.
VagueJ.The degree of masculine differentiation of obesities: A factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease. Am J Clin Nutr1956; 4: 20–34.
109.
KissebahAHVydelingumNMurrayREvansDJHartzAJKalkhoffRKRelation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab1982; 54: 254–60.
110.
KrotkiewskiMBjörntorpPSjöströmLSmithU.Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest1983; 72: 1150–62.
111.
EvansDJHoffmannRGKalkhoffRKKissebahAH. Relationship of body fat topography to insulin sensitivity and metabolic profiles in premenopausal women. Metabolism1984; 33: 68–75.
112.
PeirisANStruveMFMuellerRALeeMBKissebahAH. Glucose metabolism in obesity: Influence of body fat distribution. J Clin Endocrinol Metab1988; 67: 760–7.
113.
LandinKKrotkiewskiMSmithU.Importance of obesity for the metabolic abnormalities associated with an abdominal fat distribution. Metabolism1989; 38: 572–6.
114.
HaffnerSMKarhapääPMykkänenLLaaksoM.Insulin resistance, body fat distribution and sex hormones in men. Diabetes1994; 43: 212–9.
115.
LandinKLönnrothPKrotkiewskiMHolmGSmithU.Increased insulin resistance and fat cell lipolysis in obese but not lean women with a high waist/hip ratio. Eur J Clin Invest1990; 20: 530–5.
116.
BjörntorpP.Metabolic implications of body fat distribution. Diabetes Care1991; 14: 1132–43.
117.
KrentzAJSinghBMNattrassM.Impaired glucose tolerance is characterized by multiple abnormalities in the regulation of intermediary metabolism. Diabet Med1991; 8: 848–54.
118.
SwislockiALMChenY-DIGolayAChangM-DReavenGM. Insulin suppression of plasma free fatty acid concentration in normal individuals and patients with type 2 (non-insulin-dependent) diabetes. Diabetologia1987; 30: 622–6.
119.
SinghBMPalmaMNattrassM.Multiple aspects of insulin resistance—comparison of glucose and intermediary metabolite response to incremental insulin infusion in IDDM subjects of short and long duration. Diabetes1987; 36: 740–8.
FerranniniEDeFronzoRASherwinRJ. Transient hepatic response to glucagon in man: Role of insulin and hyperglycaemia. Am J Physiol1982; 242: E73–81.
122.
KotzmannHLinkeschMLudvikBClodiMLugerASchernthanerGEffect of danazolinduced chronic hyperglucagonaemia on glucose tolerance and turnover. Eur J Clin Invest1995; 25: 942–7.
123.
LemboGCapaldoBRendinaVIaccarinoGNapoliRGuidaRAcute noradrenergic activation induces insulin resistance in human skeletal muscle. Am J Physiol1994; 266: E242–7.
124.
MarangouAGAlfordFPWardGLiskaserFAitkenPMWeberKMHormonal effects of norepinephrine on acute glucose disposal in humans: A minimal model analysis. Metabolism1988; 37: 885–91.
125.
CapaldoBNapoliRDi MarinoLSaccàL.Epinephrine directly antagonizes insulin-mediated activation of glucose uptake and inhibition of free fatty acid release in forearm tissues. Metabolism1992; 41: 1146–9.
126.
WaltersJMWardGMKalfasABestJDAlfordFP. The effect of epinephrine on glucose-mediated and insulin-mediated glucose disposal in insulin-dependent diabetes. Metabolism1992; 41: 671–7.
127.
GerichJELorenziMBierDMTsalikianESchneiderVKaramJHEffects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin. J Clin Invest1976; 57: 875–84.
128.
RizzaRAMandarinoLJGerichJE. Effects of growth hormone on insulin action in man. Mechanism of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilisation. Diabetes1982; 31: 663–9.
RizzaRAMandarinoLJGerichJE. Cortisol-induced insulin resistance in man: Impaired suppression of glucose production and stimulation of glucose utilisation due to a postreceptor defect of insulin action. J Clin Endocrinol Metab1982; 54: 131–8.
131.
YasudaKHinesEIIIKitabchiAE. Hypercortisolism and insulin resistance: Comparative effects of prednisone, hydrocortisone and dexamethasone on insulin binding of human erythrocytes. J Clin Endocrinol Metab1982; 55: 910–5.
132.
SandlerMPRobinsonRPRabinDLacyWWAbumradNN. The effect of thyroid hormones on gluconeogenesis and forearm metabolism in man. J Clin Endocrinol Metab1983; 56: 479–85.
133.
Bratusch-MarrainPRKomsatiMWaldhäuslWK. Glucose metabolism in noninsulin-dependent diabetic patients with experimental hyperthyroidism. J Clin Endocrinol Metab1985; 60: 1063–8.
134.
FossMCPaccolaGMGFSaadMJAPimentaWPPiccinatoCEIazagiN.Peripheral glucose metabolism in human hyperthyroidism. J Clin Endocrinol Metab1990; 70: 1167–72.
135.
ShenD-CDavidsonMBKuoS-WSheuWH-H.Peripheral and hepatic insulin antagonism in hyperthyroidism. J Clin Endocrinol Metab1988; 66: 565–9.
136.
RandinJ-PTappyLScazzigaBJequierEFelberJP. Insulin sensitivity and exogenous insulin clearance in Graves' disease. Measurement by the glucose clamp technique and continuous indirect calorimetry. Diabetes1986; 35: 178–81.
GinsbergHOlefskyJMReavenGM. Evaluation of insulin resistance in patients with primary hyperparathyroidism. Proc Soc Exp Biol Med1975; 148: 942–5.
140.
FlierJSEastmanJCMinakerKMattesonDRoweJW. Acanthosis nigricans in obese women with hyperandrogenism. Characterization of an insulin-resistant state disinct from the type A and B syndromes. Diabetes1985; 34: 101–7.
141.
ChangRJNakamuraRMJuddHCKaplanSA. Insulin resistance in nonobese patients with polycystic ovary disease. J Clin Endocrinol Metab1983; 57: 356–9.
142.
StuartCAPetersEJPrinceMJRichardsGCavalloAMeyerWJIII. Insulin resistance with acanthosis nigricans: The role of obesity and androgen excess. Metabolism1986; 35: 197–205.
143.
BarbieriRLSmithSRyanKS. The role of hyperinsulinaemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril1988; 50: 197–212.
144.
DunaifAGreenGFutterweitWDobrjanskyA.Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab1990; 70: 699–704.
145.
Diamanti-KandarakisEMitrakouAHennesMMPlatanissiotisDKaklasNSpinaJInsulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism1995; 44: 525–31.
146.
NestlerJEBarlasciniCOMattDWSteingoldKAPlymateSRCloreJNSuppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab1989; 68: 1027–32.
147.
DunaifAScottDFinegoodDQuintanaBWhitcombR.The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab1996; 81: 3299–306.
148.
RosenbaumDHaberRJDunaifA.Insulin resistance in polycystic ovary syndrome: Decreased expression of GLUT-4 glucose transporters in adipocytes. Am J Physiol1993; 264: E197–202.
149.
Hugh-JonesPA. Diabetes in Jamaica. Lancet1955; ii: 891–7.
150.
ModanMHalkinHAlmogSLuskyAEshkolAShefiMHyperinsulinaemia—a link between hypertension, obesity and glucose intolerance. J Clin Invest1985; 75: 809–17.
151.
LindLLithellHPollareT.Is it hyperinsulinaemia or insulin resistance that is related to hypertension and other metabolic cardiovascular risk factors?J Hypertens1993; 11 (Suppl 4): S11-6.
152.
FerrariPWeidmannPShawSGiachinoDRiesenWAllemannYAltered insulin sensitivity, hyperinsulinaemia and dyslipidaemia in individuals with a hypertensive parent. Am J Med1991; 91: 589–96.
153.
ZavaroniIMazzaSDall'AglioEGaspariniPPasseriMReavenGM. Prevalence of hyperinsulinaemia in patients with high blood pressure. J Intern Med1992; 231: 235–40.
154.
PollareTLithellHBerneC.Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism1990; 39: 167–74.
155.
PontiroliAEAlberettoMPozzaG.Patients with insulinoma show insulin resistance in the absence of arterial hypertension. Diabetologia1992; 35: 294–5.
156.
VettorRMazzonettoPMacorCScandellariCFederspilG.Effect of endogenous organic hyperinsulinaemia on blood pressure and serum triglycerides. Eur J Clin Invest1994; 24: 350–4.
157.
SaadMFKnowlerWCPettittDJNelsonRGMottDMBennettPH. Insulin and hypertension—relationship to obesity and glucose intolerance in Pima Indians. Diabetes1990; 39: 1430–5.
158.
SaadMFLilliojaSNyombaBLCastilloCFerraroRDeGregorioMRacial differences in the relation between blood pressure and insulin resistance. N Engl J Med1991; 324: 733–9.
159.
MullerDCElahiDPratleyRETobinJDAndresR.An epidemiological test of the hyperinsulinaemia—hypertension hypothesis. J Clin Endocrinol Metab1993; 76: 544–8.
160.
LaaksoMPyöräläKVoutilainenEMarniemiJ.Plasma insulin and serum lipids and lipoproteins in middle-aged noninsulin-dependent diabetic and nondiabetic subjects. Am J Epidemiol1987; 125: 611–21.
161.
TaskinenM-RHelveENikkilaEAYki-JärvinenH.Insulin therapy induces antiatherogenic changes in lipoproteins of type 2 diabetics. Diabetes1987; 36 (suppl): 81A.
162.
LindströmTArnqvistHJOlssonAG. Effects of different insulin regimens on plasma lipoprotein and apolipoprotein concentrations in patients with noninsulin-dependent diabetes mellitus. Atherosclerosis1990; 81: 137–44.
163.
ScarlettJAGrayRSGriffinJOlefskyJMKoltermanOG. Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care1982; 5: 353–63.
164.
DavisCEGordonDLaRosaJWoodPDSHalperinM.Correlation of plasma high density lipoprotein cholesterol levels with other plasma lipid and lipoprotein concentrations. The Lipid Research Clinics Program Prevalence Study. Circulation1980; 62 (suppl IV): IV-24–30.
165.
KarhapääPMalkkiMLaaksoM.Isolated low HDL-cholesterol: An insulin resistant state. Diabetes1994; 43: 411–7.
166.
OlefskyJMFarquharJWReavenGM. Reappraisal of the role of insulin in hypertriglyceridaemia. Am J Med1974; 57: 551–60.
167.
BernsteinRMDavisBMOlefskyJMReavenGM. Hepatic insulin responsiveness in patients with endogenous hypertriglyceridaemia. Diabetologia1978; 14: 249–53.
168.
SteinerGMoritaSVranicM.Resistance to insulin but not to glucagon in lean human hypertriglyceridaemics. Diabetes1980; 29: 899–905.
169.
WidénEEkstrandASalorantaCFranssila-KallunkiAErikssonJSchalin-JänttiCInsulin resistance in type 2 (non-insulin dependent) diabetic patients with hypertriglyceridaemia. Diabetologia1992; 35: 1140–5.
170.
McKaneWRStevensABWoodsRAndrewsWJHenryRWBellPM. The assessment of hepatic and peripheral insulin sensitivity in hypertriglyceridaemia. Metabolism1990; 39: 1240–5.
171.
EckelRH. Lipoprotein lipase—a multifunctional enzyme relevant to common metabolic diseases. N Engl J Med1989; 320: 1060–8.
172.
Yki-JärvinenHTaskinenM-R.Interrelationships among insulin's antilipolytic and glucoregulatory effects and plasma triglycerides in nondiabetic and diabetic patients with endogenous hypertriglyceridaemia. Diabetes1988; 37: 1271–8.
173.
ReavenGM. Pathophysiology of insulin resistance in human disease. Physiol Rev1995; 75: 473–86.
174.
KaplanNM. The deadly quartet—upper body obesity, glucose intolerance, hypertriglyceridaemia and hypertension. Arch Intern Med1989; 149: 1514–20.
175.
FerranniniEHaffnerSMMitchellBDSternMP. Hyperinsulinaemia: The key feature of a cardiovascular and metabolic syndrome. Diabetologia1991; 34: 416–22.
176.
DeFronzoRAFerranniniE.Insulin resistance—a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerotic cardiovascular disease. Diabetes Care1991; 14: 173–94.
177.
IngelfingerJABennettPHLiebowIMMillerM.Coronary heart disease in the Pima Indians. Diabetes1976; 25: 561–5.
178.
NeelJV. Diabetes mellitus: A ‘thrifty’ genotype rendered detrimental by ‘progress’?Am J Hum Genet1962; 14: 353–62.
179.
ZimmetP.Hyperinsulinaemia—how innocent a bystander?Diabetes Care1993; 16 (suppl 3): 56–70.
180.
WendorfMGoldfineID. Archaeology of NIDDM. Excavation of the ‘thrifty’ genotype. Diabetes1991; 40: 161–5.
181.
BarkerDJP. The Wellcome Foundation Lecture 1994: The fetal origins of adult disease. Proc Roy Soc Lond (series B) 1995; 262: 37–43.
182.
BarkerDJPHalesCNFallCHDOsmondCPhippsKClarkPMS. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): Relation to reduced fetal growth. Diabetologia1993; 36: 62–7.
183.
PhillipsDIWBarkerDJPHalesCNHirstSOsmondC.Thinness at birth and insulin resistance in adult life. Diabetologia1994; 37: 150–4.
184.
SternM.Diabetes and cardiovascular disease. The ‘Common Soil’ hypothesis. Diabetes1995; 44: 369–74.
185.
ZavaroniIBonoraEPagliariMDall'AglioELucchettiLBuonannoGRisk factors for coronary artery disease in healthy persons with hyperinsulinaemia and normal glucose tolerance. N Engl J Med1989; 320: 702–6.
186.
HaffnerSMValdezRAHazudaHPMitchellBDMoralesPASternMP. Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes1992; 41: 715–22.
187.
StoutRW. Diabetes and atherosclerosis—the role of insulin. Diabetologia1979; 16: 141–50.
188.
StoutRW. Insulin and atheroma—an update. Lancet1987; i: 1077–9.
189.
JarrettRJ. Is insulin atherogenic?Diabetologia1988; 31: 71–5.
190.
JarrettRJ. In defence of insulin: A critique of syndrome X. Lancet1992; 340: 469–71.
191.
WidénEIMErikssonJGGroopLC. Metformin normalises nonoxidative glucose metabolism in insulin-resistant normoglycaemic first-degree relatives of patients with NIDDM. Diabetes1992; 41: 354–8.
192.
BaileyCJ. Biguanides and NIDDM. Diabetes Care1992; 15: 755–72.
193.
SchoonjansK.StaelsBAuwerxJ. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta1996; 1302: 93–109.
194.
KolaczynskiJWNyceMRConsidineRVBodenGNolanJJHenryRAcute and chronic effects of insulin on leptin production in humans: Studies in vivo and in vitro. Diabetes1996; 45: 699–701.
195.
SegalKRLandtMKleinS.Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes1996; 45: 988–91.
196.
de CourtenMZimmetPHodgeACollinsVNicolsonMStatenMHyperleptinaemia: The missing link in the metabolic syndrome?Diabet Med1997; 14: 200–8.
197.
ConsidineRVSinhaMKHeimanMLKriauciunasAStephensTWNyceMRSerum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med1996; 334: 292–5.
198.
RosenbaumMNicolsonMHirschJHeymsfieldSBGallagherDChuFEffects of gender, body composition, and menopause on plasma concentrations of leptin. J Clin Endocrinol Metab1996; 81: 3424–7.
199.
OfeiFHurelSNewkirkJSopwithMTaylorR.Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycaemic control in patients with NIDDM. Diabetes1996; 45: 881–5.
200.
YoungAPittnerRGedulinBVineWRinkT.Amylin regulation of carbohydrate metabolism. Biochem Soc Trans1995; 23: 325–31.
201.
BennetWMSmithDMBloomSR. Islet amyloid polypeptide: Does it play a pathophysiological role in the development of diabetes?Diabet Med1994; 11: 825–9.
202.
ErikssonJWLönnrothPPosnerBIShaverAWesslauCSmithUPG. A stable peroxovanadium compound with insulin-like action in human fat cells. Diabetologia1996; 39: 235–42.
203.
CohenNHalberstamMShlimovichPChangCJShamoonHRossettiL.Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest1995; 95: 2501–9.
204.
BodenGChenXRuizJvan RossumGDTurcoS.Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism1996; 45: 1130–5.
205.
BuemannBTremblayA.Effects of exercise training on abdominal obesity and related metabolic complications. Sports Med1996; 21: 191–212.